Claims
- 1. A compound of the formula wherein R is CH3, C2H5, CH2CH2CH3, CH(CH3)2, CH═CH2, CH2CH═CH2, CH═CHCH3,R1 is wherein X is, H, OCH3 or Cl and Y is H, OCH3 or Cl, and n=1-8,with the proviso that when X and Y are H, n cannot equal 1.
- 2. The compound of claim 1, wherein R is C2H5.
- 3. The compound of claim 1, wherein R is CH2CH3CH3.
- 4. The compound of claim 1, wherein R is CH(CH3)2.
- 5. The compound of claim 1, wherein R1 is
- 6. The compound of claim 5, wherein X is H and Y is OCH3.
- 7. The compound of claim 5, wherein X is OCH3 and Y is H.
- 8. The compound of claim 5, wherein X is OCH3 and Y is OCH3.
- 9. The compound of claim 5, wherein X is Cl and Y is H.
- 10. The compound of claim 5, wherein X is H and Y is Cl.
- 11. The compound of claim 5, wherein X is Cl and Y is Cl.
- 12. A method for treating psychostimulant abuse, by administering to a patient in need of such treatment a pharmaceutically effective amount of the compound of claim 1.
- 13. A method for inhibiting the action of a psychostimulant, by administering to a patient in need of such treatment a psychostimulant-inhibiting amount of the compound of claim 1.
- 14. A method for inhibiting neurotransmitter re-uptake by administering to a patient in need of such treatment a neurotransmitter transporter-inhibiting amount of the compound of claim 1, wherein said neurotransmitter is dopamine, serotonin or norepinephrine.
- 15. A method for treating Parkinson's Disease, by administering to a patient in need of such treatment a pharmaceutically effective amount of the compound of claim 1.
- 16. A method for treating depression, by administering to a patient in need of such treatment a pharmaceutically effective amount of the compound of claim 1.
- 17. A compound of the formula: whereinR=hydrogen, or C1-5 alkyl, Y=OCH3, or Cl, and Z=H, I, Br, Cl, F, CN, CF3, NO2, N3, OR1, CONH2, CO2R1, C1-6 alkyl, NR4R5, NHCOR5, NHCO2R6, wherein R4, R5, R6 are each C1-6 alkyl or wherein R1, R2, R3=H or C1-4 alkyl.
- 18. A compound of the formula: whereinR1=hydrogen or C1-5 alkyl, X=H, C1-6 alkyl, C3-8 cycloalkyl, C1-4 alkoxy, C1-6 alkynyl, halogen, amino or acylamido, Y=H, OCH3 or Cl, Z=H, I, Br, Cl, F, CN, CF3, NO2, N3, OR1, CONH2, CO2R1, C1-6 alkyl, NR4R5, NHCOR5, NHCO2R6 or wherein R4-R6 are each independently C1-6 alkyl, or —C≡C—R1 R1, R2, R3=H or C1-4 alkyl and M=(CH2)x, wherein x=1-8, —CH═CH— or —C≡C—.
Parent Case Info
This application is a continuation-in-part application of U.S. patent application Ser. No. 08/506,541, filed Jul. 24, 1995 now abandoned, which is a continuation-in-part of (1) U.S. patent application Ser. No. 07/972,472, filed Mar. 23, 1993, which issued May 9, 1995 as U.S. Pat. No. 5,413,779; (2) U.S. patent application Ser. No. 08/164,576, filed Dec. 10, 1993 U.S. Pat. No. 5,496,953, which is in turn a continuation-in-part of U.S. patent application Ser. No. 07/792,648, filed Nov. 15, 1991, now U.S. Pat. No. 5,380,848, which is in turn a continuation-in-part of U.S. patent application Ser. No. 07/564,755, filed Aug. 9, 1990, now U.S. Pat. No. 5,128,118 and U.S. PCT Application PCT/US91/05553, filed Aug. 9, 1991, filed in the U.S. PCT Receiving Office and designating the United States; and (3) U.S. patent application Ser. No. 08/436,970, filed May 8, 1995 U.S. Pat. No. 5,736,123, all of which are incorporated herein by reference in their entirety.
US Referenced Citations (9)
Foreign Referenced Citations (1)
Number |
Date |
Country |
WO 9309814 |
May 1993 |
WO |
Non-Patent Literature Citations (7)
Entry |
Reith MEA et al. Biochemical Pharmacology. 35(7), 1123-1129, 1986.* |
Australian Office Action Dated Jan. 25, 2000, 2pp. |
J. Med. Chem. (JMCMAR, 00222623); Mar. 20, 1992; vol.35(6); pp. 969-981, XP002116827, Research Triangle Inst.; Research Triangle Park; 27709; NC; USA. |
Nida Res. Monogr. (MIDAD4, 03618595); 1990; vol.96 (Drugs Abuse: Chem., Pharmacol., Immunol., AIDS); pp.112-121, XP002116828, Research Triangle Inst.; Research Triangle Park; 27709; NC; USA. |
J. Med. Chem. (JMCMAR, 00222623); 1993; vol.36(20); pp. 2886-2890, XP002116829, Research Triangle Inst.; Research Triangle Park; 27709; NC; USA. |
Carroll F I Et Al: “Synthesis and ligand binding of 3,beta.-(3-substituted phenyl)-and 3.beta.-(3,4-disubstituted phenyl)tropane-2.beta.-carboxylic acid methyl esters” Med. Chem. Res. (McReeb, 10542523); 1991; vol.1(6); pp.382-387, XP002116826, Research Triangle Inst.; Research Triangle Park; 27709; NC; USA. |
Maarten E. A. Reith et al., “Structural Requirements For Cocaine Congeners to Interact With Dopamine and Serotonin Uptake Sites in Mouse Brain and to Induce Stereotyped Behavior”, Biochemical Pharmacology, vol. 35, No. 7, pp. 1123-1129, 1986. |
Continuation in Parts (7)
|
Number |
Date |
Country |
Parent |
08/506541 |
Jul 1995 |
US |
Child |
08/706263 |
|
US |
Parent |
08/436970 |
May 1995 |
US |
Child |
08/506541 |
|
US |
Parent |
08/164576 |
Dec 1993 |
US |
Child |
08/436970 |
|
US |
Parent |
07/972472 |
Mar 1993 |
US |
Child |
08/164576 |
|
US |
Parent |
07/792648 |
Nov 1991 |
US |
Child |
07/972472 |
|
US |
Parent |
PCT/US91/05553 |
Aug 1991 |
US |
Child |
07/792648 |
|
US |
Parent |
07/564755 |
Aug 1990 |
US |
Child |
PCT/US91/05553 |
|
US |